Device Trial Radar · NCT07246902
Mobilization and Outcomes After Venous Closure
Last checked: Nov 20, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
339
Actual
Start
Nov 24, 2025
Primary completion
Aug 26, 2026
Study completion Aug 26, 2026
Sponsor
- Lead sponsor
- Cordis US Corp.Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- NAMSA
- First posted
- Nov 24, 2025
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this post-market registry is to collect real-world outcomes and evaluate usage practice of MYNX CONTROL™ VENOUS (MCV) Vascular Closure Device (VCD) 6F-12F in sealing femoral venous access sites in patients who have undergone endovascular procedures in a real-world setting.
Conditions
- Venous Vascular Closure
- Electrophysiology Study
Interventions
MYNX CONTROLTM VENOUS Vascular Closure DeviceDevice
The MYNX CONTROLTM VENOUS (MCV) Vascular Closure Device (VCD) 6F-12F is indicated for use to seal femoral venous access sites while reducing times to hemostasis and ambulation in patients who have undergone diagnostic or interventional endovascular procedures utilizing 6F to 12F procedural sheaths, with single or multiple access sites in one or both limbs. MCV VCD is designed to achieve femoral vein hemostasis via delivery of the GRIP TECHNOLOGY™ sealant (an extravascular, water-soluble synthetic hydrogel), using a balloon catheter in conjunction with a standard procedural sheath. The sealant is made of a polyethylene glycol (PEG) material which expands upon contact with subcutaneous fluids to seal the venotomy and is resorbed by the body within 30 days. The MCV VCD is supplied with a 10ml locking syringe used for balloon inflation and deflation. The catheter shaft has a silicone lubricant to facilitate insertion and withdrawal into compatible sheaths.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of patients with same day discharge (SDD) and without subsequent hospitalization/intervention for access-site complicationsTime frame: From time of index procedure through end of following day (within 48 hours)
- Rate of access-site complicationsTime frame: From time of study device introduction at first access site through 14 days post-procedure
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Cedars Sinai Medical Center
Los Angeles, California
Stanford University School of Medicine
Palo Alto, California
South Denver Cardiology
Littleton, Colorado
6 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.